Ignacio Tusquets

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacology +17

The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma

Cristina Corzo, Josep Corominas, Ignacio Tusquets et al. · Cancer Genetics and Cytogenetics · 2006 · 53 citations

Medicine, Molecular Biology, Oncology +16

Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Roisin E. O’Cearbhaill, José Alejandro Pérez Fidalgo, Bradley J. Monk et al. · Gynecologic Oncology · 2022 · 36 citations · Full text

Medicine, Oncology, Surgery +17

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors

Alma Carracedo, Kristóf Égervári, Marta Salido et al. · Breast Cancer Research · 2009 · 26 citations · Full text

Medicine, Oncology, Pathology +17

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

Agustí Barnadas, Luís Manso, Concepción de la Piedra et al. · Bone · 2014 · 18 citations · Full text

Medicine, Oncology, Bone Metabolism +16